Incyte Corporation intraday rises 1.23% after Silo Pharma's $2.1M fundraising and MAIA Biotechnology's comment on telomere targeting.

Incyte Corporation experienced a 1.227% intraday rise during trading. The stock's upward movement was potentially influenced by the news that Silo Pharma announced the closing of a $2.1 million registered direct offering, which included the issuance of warrants for common stock and the company's focus on innovative drug delivery systems for traditional and psychedelic treatments. This financing could boost investor optimism in Silo Pharma's future prospects, even though the company is not directly related to Incyte Corporation's operations.